Top news of the day from across the health care landscape.
Hepatitis/MASH
Latest News
Advertisement
CME Content
Advertisement
More than 3 million Americans have chronic hepatitis C virus, and physicians diagnose about 17,000 new cases annually.
An experimental antiviral drug shows promise fighting multiple infectious diseases.
Patients who achieved hepatitis C virus eradication experienced a reduction in hepatic steatosis and fibrosis.
Researchers from the CDC assessed adverse effects (AEs) following HepB vaccinations using the Vaccine Adverse Event Reporting System (VAERS).
The CDC and the American Academy of Pediatrics released an updated vaccination schedule.
T cell alterations could exacerbate acute hepatitis infections.
Nearly all people who inject drugs with hepatitis C virus achieved a sustained virologic response at 12 weeks.
Ribavirin steady-state serum levels correspond to high rates of efficacy and low adverse effect from direct-acting antiviral drugs for difficult-to-treat hepatitis C virus.
The opioid epidemic has led to an increase in HCV-positive liver donations.
Top news of the day from across the healthcare landscape.
Top news of the day from across the health care landscape.
Screening for HBV among high-risk populations is crucial to stopping transmission of the virus.
Glecaprevir and pibrentasvir (Mavyret) shows efficacy across hepatitis C genotypes.
Direct-acting antivirals drugs show similar cure rates in co-infected patients as high as mono-infected patients.
Significant gains have been made against viral hepatitis.
Top news of the day from across the healthcare landscape.
Top news of the day from across the healthcare landscape.
Nine other countries are on track to eliminate the hepatitis C virus by 2030.
Officials with the FDA have approved an adjuvanted hepatitis B vaccine, recombinant [Heplisav-B, Dynavax] for the prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older.
Top news of the week from Specialty Pharmacy Times.
Heplisav-B is the only 2-dose hepatitis B vaccine recombinant approved in the United States.
Patients without cirrhosis who achieved a sustained virological response had the lowest risk of hepatocellular carcinoma linked to hepatitis C virus.
Top news of the day from across the healthcare landscape.
Top news of the day from across the healthcare landscape.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Emerging Biomarkers Open New Frontiers in Lung Cancer Therapy
2
Dato-DXd Doubles Response Rates and Extends Survival in First-Line Metastatic TNBC
3
Targeted α-Particle Radioligand Therapy Shows Promising Activity, Low Toxicity in SSTR2-Positive Neuroendocrine Tumors
4
Weekly Paclitaxel May Hold the Key to Pembrolizumab’s Success in Platinum-Resistance Ovarian Cancer
5
